• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Treatment Algorithms: Psoriasis - Prescribing Trends Mirror Guidelines


News provided by

Reportlinker

Mar 20, 2012, 07:11 ET

Share this article

Share this article


NEW YORK, March 20, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Treatment Algorithms: Psoriasis – Prescribing trends mirror guidelines

http://www.reportlinker.com/p0799251/Treatment-Algorithms-Psoriasis-–-Prescribing-trends-mirror-guidelines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Prescribing trends at earlier lines of therapy remain relatively unchanged. However, biologics Enbrel (etanercept; Amgen/Pfizer), Humira (adalimumab; Abbott/Eisai), and Stelara (ustekinumab; Janssen Biotech) continue to reshape the management of moderate to severe psoriasis patients. This trend is expected to continue over the next decade, as physicians gain clinical experience with these agents. Enhance understanding of patient flow and estimate the size of the psoriasis patient pool using interactive country-specific treatment trees. Assess the regional dynamics of pharmacological therapy (topical and systemic agents) choice in psoriasis. Access a snapshot of current patient-numbers receiving drug therapy at first line and second line and beyond (following first line therapy failure). Gain insight into how formulation impacts compliance and how this changes according to disease severity. Dermatologists reveal that most psoriasis patients receive a combination of drug and non-drug therapy to manage symptoms, with a seven major market mean of 36.1% of mild diagnosed patients receiving this treatment strategy, rising to 52.1% in severe patients. However, this is unsurprising and mirrors treatment guidelines for psoriasis. Biologics Enbrel and Humira continue to be heavily prescribed by dermatologists at first line for moderate to severe patients. In the US and EU, Stelara has gained traction and Datamonitor anticipates that greater familiarity and experience with its safety profile will fuel its ascendance across the seven major markets over the coming decade. Across all disease severities, the chief reason for psoriasis patients not progressing to second line and beyond of drug therapy is the exploration of other forms of non-drug therapy. Datamonitor speculates that the high annual cost of therapies such as biologics steers patients to seek cheaper, non-drug alternatives to control their symptoms. Which topical and biologic brands experience the greatest physician uptake in each seven major market? To what extent is Stelara challenging established biologic drugs Enbrel and Humira from dermatologists' viewpoint? What are the current psoriasis market dynamics and the competitive landscape in terms of patient numbers?

OVERVIEWCatalystSummaryEXECUTIVE SUMMARYStrategic scoping and focusDatamonitor key findingsRelated reportsCOUNTRY TREATMENT TREESIntroduction to treatment treesUSJapanFranceGermanyItalySpainUKDISEASE DEFINITION AND DIAGNOSISDisease definition EtiologyThe exact etiology of psoriasis remains unknownSymptomsVariant types of psoriasis display different symptomsPresentation and diagnosisTime to diagnosis: psoriasis patients wait over 10 months before presentingPATIENT SEGMENTATIONSeverity: moderate sufferers are the largest patient segmentCURRENT TREATMENT OPTIONSPharmacological versus non-pharmacological Most psoriasis patients are treated with non-pharmacological and pharmacological therapyCountry trends: most notable is the heavy reliance on pharmacological therapy by Japanese physiciansOverview of the available drug classesPrescribing trendsUse of combination therapy generally increases with disease severity and line of therapyBiologic usage by brand and line of therapyMajority of patients not progressing to second line and beyond of therapy explore other forms of non-pharmacological therapy Changes in therapyCompliance increases with disease severity and from topical to systemic therapiesTreatment outcomesMost mild patients reach desired outcomes after 6 months of treatmentBIBLIOGRAPHYJournal papersWebsitesDatamonitor reportsAPPENDIX A – SURVEY INFORMATIONPhysician research methodology 2011The 2011 survey questionnairePhysician research methodology 2009The 2009 survey questionnaireAPPENDIX BContributing expertsReport methodology

TABLES

Table: Mean percentage of psoriasis patients with each sub-type of the disease, by country (%), 2011

Table: Total length of time from onset of symptoms to psoriasis diagnosis across the seven major markets (months)

Table: Mean percentage of diagnosed psoriasis patients with each severity, by country (%), 2011

Table: Mean percentage of psoriasis patients treated with various forms of therapy, across the seven major markets, by disease severity, 2011

Table: Leading treatments in psoriasis, 2012

Table: Mean percentage of psoriasis patients receiving monotherapy versus combination therapy, by severity, line of therapy, and country (%), 2011

Table: Mean percentage of psoriasis patients across the seven major markets receiving each biologic, by line of therapy, severity, and country (%), 2011

Table: Reasons why patients do not progress to second-line pharmacological therapy and beyond, percentage of respondents, by severity and country (%), 2011

Table: Mean compliance rates for psoriasis patients in each of the seven major markets, by formulation and severity (%, n), 2011

Table: Mean percentage of psoriasis patients reaching the desired outcome after 6 months of treatment across the seven major markets, by severity (%)

Table: Dermatologists surveyed regarding psoriasis across the seven major markets

Table: Percentage of diagnosed psoriasis patients suffering with mild, moderate, and severe disease

Table: Percentage of all psoriasis patients suffering with each sub-type of psoriasis

Table: Percentage of psoriasis patients treated with a particular type of therapy

Table: Compliance rate percentage for psoriasis patients at each severity, receiving each formulation type (%), 2011

Table: Dermatologists surveyed regarding psoriasis across the seven major markets

FIGURES

Figure: US psoriasis diagnosed patient population, by physician-estimated treatment rates for each disease severity and usage of key brands at first line (%, n), 2011Figure: US psoriasis patients progressing to drug therapy at second line and beyond following first-line therapy failure (%, n), 2011Figure: Japan psoriasis diagnosed patient population, by physician-estimated treatment rates for each disease severity and usage of key brands at first line (%, n), 2011Figure: Japan psoriasis patients progressing to drug therapy at second line and beyond following first-line therapy failure (%, n), 2011Figure: France psoriasis diagnosed patient population, by physician-estimated treatment rates for each disease severity and usage of key brands at first line (%, n), 2011Figure: France psoriasis patients progressing to drug therapy at second line and beyond following first-line therapy failure (%, n), 2011 Figure: Germany psoriasis diagnosed patient population, by physician-estimated treatment rates for each disease severity and usage of key brands at first line (%, n), 2011Figure: Germany psoriasis patients progressing to drug therapy at second line and beyond following first-line therapy failure (%, n), 2011 Figure: Italy psoriasis diagnosed patient population, by physician-estimated treatment rates for each disease severity and usage of key brands at first line (%, n), 2011Figure: Italy psoriasis patients progressing to drug therapy at second line and beyond following first-line therapy failure (%, n), 2011 Figure: Spain psoriasis diagnosed patient population, by physician-estimated treatment rates for each disease severity and usage of key brands at first line (%, n), 2011Figure: Spain psoriasis patients progressing to drug therapy at second line and beyond following first-line therapy failure (%, n), 2011 Figure: UK psoriasis diagnosed patient population, by physician-estimated treatment rates for each disease severity and usage of key brands at first line (%, n), 2011Figure: UK psoriasis patients progressing to drug therapy at second line and beyond following first-line therapy failure (%, n), 2011Figure: Key features of the current understanding of psoriasis pathogenesis, with an illustration of targets for clinical candidates and marketed therapiesFigure: Total length of time from onset of symptoms to psoriasis diagnosis across the seven major marketsFigure: Physicians indicating that psoriasis is diagnosed immediately upon presentation versus those who believe that patients experience a delay in receiving a diagnosisFigure: Mean percentage of diagnosed psoriasis patients with each severity, by country (%), 2011Figure: Mean percentage of psoriasis patients treated with various forms of therapy, across the seven major markets, by disease severity, 2011Figure: Mean percentage of psoriasis patients receiving monotherapy versus combination therapy, by severity, line of therapy across the seven major markets (%), 2011Figure: Mean percentage of psoriasis patients receiving each biologic across the seven major markets, by line of therapy and severity (%), 2011Figure: Reasons why patients do not progress to second-line pharmacological therapy and beyond, percentage of respondents, by severity (%), 2011Figure: Mean compliance rates for psoriasis patients, by formulation and severity across the seven major markets (%), 2011Figure: Distribution of physician responses for percentage of patients reaching the desired outcome, by severity (%)Figure: Treatment flow: mild – first-line pharmacological therapy (initial therapy prescribed)Figure: Treatment flow: mild – second-line pharmacological therapy and beyondFigure: Treatment flow: moderate – first-line pharmacological therapy (initial therapy prescribed)Figure: Treatment flow: moderate – second-line pharmacological therapy and beyondFigure: Treatment flow: severe – first-line pharmacological therapy (initial therapy prescribed)Figure: Treatment flow: severe – second-line pharmacological therapy and beyond

Companies mentioned

GlaxoSmithKline Plc, Hutchison 3G UK Limited, Johnson & Johnson, RSA Insurance Group plc

To order this report:Pathology Industry: Treatment Algorithms: Psoriasis – Prescribing trends mirror guidelines

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.